The short answer
Dandelion herb warrants glucose review with insulin glulisine, but the clinical report involved NPH insulin. The exact glulisine combination and a safe herb amount remain unestablished.
What this answer covers
Herba Taraxaci herbal material; salad exposure in the case does not identify every plant part, extract or root product.
- Supplement or preparation
- Herba Taraxaci
- Medication ingredient
- insulin glulisine, human
One report provides a limited signal
A woman taking NPH insulin developed symptomatic low glucose after adding dandelion to salads. Symptoms stopped after she discontinued it. Recent insulin changes and the uncontrolled design limit attribution.
The insulin and preparation differ
NPH is an intermediate-acting insulin, whereas Apidra is rapid-acting glulisine. The report does not verify the plant part or amount, so it cannot establish a glulisine-specific rate or safe herb dose.
Keep the meal plan tied to Apidra
For subcutaneous mealtime injection, Apidra’s label specifies within15minutes before a meal or within20minutes after starting it. Pump use and medically supervised intravenous treatment have separate instructions.
Review the addition before changing treatment
Discuss dandelion use with the diabetes team and follow your glucose-monitoring and low-glucose treatment plan. Do not adjust insulin yourself. No herb-spacing interval is established to prevent a possible glucose effect.
Evidence and practical considerations
Side effects & toxicity
An indirect NPH-insulin case supports a cautious glucose review, without proving glulisine-specific causation or defining the Herba preparation.
- Exact scope
- Herba Taraxaci herbal material; salad exposure in the case does not identify every plant part, extract or root product. with Insulin glulisine human RxCUI400008 IN; Apidra product and routes.
- Medication form and route
- injected insulin glulisine; oral supplement
What remains uncertain
- No exact-pair event rate or universal insulin adjustment established.
Factors that may matter: Product; Dose; Meal pattern; Other glucose-active treatments.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes prescribed Apidra
Hypoglycemia can be severe. Niacin may decrease glucose-lowering effect. Changed glucose-active treatment may require more monitoring and clinician-directed dose review. Subcutaneous mealtime injection within15minutes before or20minutes after meal start.
How this applies: Exact insulin glulisine product and routes independently checked.
General insulin risks do not establish an herb-specific adverse-event rate. Other insulins and premixes have different action and meal instructions.
Source 2: original case report
doi.org · Source check Sep 10, 2026
Population: One woman with type2 diabetes
Symptomatic low glucose resolved after dandelion cessation.
How this applies: Indirect insulin-class signal; exact Herba Taraxaci preparation uncertain.
Single uncontrolled report, recent insulin dose changes; plant part and amount unverified. Not glulisine.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact glulisine article with independently inspected Apidra label and source-specific clinical limits. | |
| Research summary published |
Article revision: 77ea800479a77183
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.